Barnes Grp - B STOCK NEWS

ASSA ABLOY (NASDAQ Stockholm: ASSA_B), a global leader in access solutions with $15.6 billion in annual sales and 63,000 employees, has acquired Pedestal PRO, a Utah-based manufacturer of access control mounting solutions.

Founded in 2002, Pedestal PRO specializes in designing and manufacturing universal and device-specific mounting solutions for security systems integrators and professionals globally. The company also offers custom design and fast-track fabrication services.

The acquisition strengthens ASSA ABLOY's presence in mature markets by enhancing its core business, as Pedestal PRO's products integrate seamlessly with ASSA ABLOY solutions. The founders and leadership team of Pedestal PRO, including CEO Pike Goss, will remain in place to support continued growth.

Hexagon AB (HEXA) has announced key leadership changes in its Manufacturing Intelligence division. Andreas Renulf will assume the role of President effective May 1, 2025, reporting to interim President and CEO Norbert Hanke. Renulf, who joined Hexagon in January 2024 as COO and Head of Machine Control for the Geosystems division, brings extensive experience from Trelleborg and ABB.

The current President, Josh Weiss, is departing to join another company and will facilitate the transition through May 2025. During his ten-year tenure at Hexagon, Weiss notably improved profitability and cash conversion in the Manufacturing Intelligence division. Renulf's appointment comes with expectations to drive growth and operational excellence, particularly in robotics and autonomy optimization for customer product lifecycles.

Lennar (NYSE: LEN) has partnered with Dandelion Energy to implement one of the largest residential geothermal deployments in US history. The collaboration will integrate Dandelion's geothermal systems into over 1,500 new Lennar homes in Colorado over the next two years.

Homeowners are expected to save approximately $30 million over 20 years compared to air-source heat pumps, offering the lowest monthly energy bills. The initiative benefits from Colorado's state tax credit and Xcel Energy's geothermal programs, significantly reducing up-front costs for homebuilders.

The project aligns with Colorado's clean energy transition goals, promising reduced carbon emissions and lower energy costs. According to the Department of Energy, widespread adoption of geothermal heat pumps could eliminate the need for 24,500 miles of new grid transmission lines.

BioArctic AB (BIOA) announced that the European Commission (EC) has referred the marketing authorization approval decision for lecanemab, their Alzheimer's treatment, to the Appeal Committee. This follows the positive opinion received from the Committee for Medicinal Products for Human Use (CHMP) in February 2025.

If approved, the authorization would extend to all 27 EU member states, plus Iceland, Liechtenstein, and Norway. The drug, marketed as Leqembi, is already approved in several major markets including the US, Japan, China, and Great Britain.

Leqembi was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease. While Eisai manages clinical development and global commercialization, BioArctic retains rights to commercialize Leqembi in the Nordic region jointly with Eisai.

Integrum AB (Nasdaq First North: INTEG B) has announced a new compensation package for Board Director and Acting CEO Scott Flora, focusing on performance-based incentives during the company's strategic transition. The package includes 200,000 Stock Appreciation Rights (SARs) with a maximum compensation of SEK 60 per SAR and a base price of SEK 29.30.

The SARs will vest at a rate of 20% every three months starting June 1, 2025, and can be exercised between September 1-October 31, 2026. Unvested SARs will lapse without payment. The company maintains flexibility to pay in either stock or cash. As part of this restructuring, Flora's fixed compensation will be reduced. This adjustment aligns with the company's executive compensation guidelines approved at the latest shareholders' meeting.

Hexagon has released its Annual Report and Sustainability Report 2024, now available on hexagon.com. The company plans to distribute the reports digitally, though printed copies can be requested via email or phone. The Annual General Meeting is scheduled for May 5, 2025, at 17:00 CET in Stockholm, with attendance notification required by April 28, 2025.

As a global leader in precision technologies, Hexagon (Nasdaq Stockholm: HEXA B) operates in 50 countries with approximately 24,800 employees and generates net sales of about 5.4bn EUR. The company specializes in digital twins, robotics, and AI solutions for industry transformation.

BioArctic AB (NASDAQ Stockholm: BIOA B) announced that its partner Eisai has released sales projections for Leqembi®. According to Eisai's simulation, Leqembi sales are expected to reach JPY 250 to 280 billion for their financial year 2027, ending March 2028.

Integrum AB (INTEG B) has announced compelling results from a two-year follow-up study conducted by Walter Reed National Military Medical Center on their OPRA™ Implant System for transfemoral amputees. The Level II Evidence study, focusing on the latest version introduced in 2017, demonstrates significant advantages over traditional socket prostheses.

The study revealed several key achievements:

• 100% implant survival rate
• Reduced infection and complication rates compared to previous data
• Increased prosthetic use
• Improved mobility and quality of life for patients

The research, published in Clinical Orthopaedics and Related Research (CORR), was conducted by a team led by Dr. Benjamin K. Potter and Dr. Jonathan Forsberg. The findings are expected to drive further adoption among US health providers and potentially increase insurance provider reimbursement coverage.

BioArctic AB (Nasdaq Stockholm: BIOA B) has received Orphan Drug Designation from the US FDA for exidavnemab, targeting the treatment of Multiple System Atrophy (MSA). MSA is a rare, fatal disease affecting the central and autonomic nervous systems, characterized by alpha-synuclein aggregation that damages brain nerve cells.

Exidavnemab is being developed as a disease-modifying treatment for synucleinopathies including MSA and Parkinson's disease. As a monoclonal antibody, it selectively targets soluble alpha-synuclein aggregates to potentially reduce their spreading and negative effects.

The FDA's Orphan Drug Designation provides several benefits, including:

• Tax credits for qualified clinical trials
• Prescription drug user-fee exemptions
• Potential seven-year marketing exclusivity upon FDA approval